euro-biotechnology-2018-keynote

7 / 8

Volume 8
Journal of Biotechnology & Biomaterials
ISSN: 2155-952X Euro Biotechnology 2018
October 11-12, 2018
conference series.com
October 11-12, 2018 | Moscow, Russia
21st European
Biotechnology Congress
Page 28
Sergey Suchkov, J Biotechnol Biomater 2018, Volume 8
DOI: 10.4172/2155-952X-C5-099
Antibodies with functionality as a new generation of translational tools to monitor, to predict
and to prevent demyelination
Absagainstmyelinbasicprotein/MBPendowingwithproteolyticactivity(Ab-proteaseswithfunctionality)isofgreatvalue
to monitor demyelination to illustrate the evolution of multiple sclerosis (MS). Anti-MBP auto-Abs from MS patients
and mice with EAE exhibited specific proteolytic cleavage of MBP which, in turn, markedly differed between: MS patients
and healthy controls; different clinical MS courses and; EDSS scales of demyelination to correlate with the disability of MS
patients to predict the transformation prior to changes of the clinical course. Ab-mediated proteolysis of MBP was shown
to be sequence-specific whilst demonstrating five sites of preferential proteolysis to be located within the immunodominant
regions of MBP and to fall inside into 5 sequences fixed. Some of the latter (with the highest encephalitogenic properties)
were proved to act as a specific inducer of EAE and to be attacked by the MBP-targeted Ab-proteases in MS patients with
the most severe (progradient) clinical courses. The other ones whilst being less immunogenic happened to be EAE inducers
very rare but were shown to be attacked by Ab-proteases in MS patients with moderate (remission-type) clinical courses.
The activity of Ab-proteases was first registered at the subclinical stages 1-2 years prior to the clinical illness. About 24% of
the direct MS-related relatives were seropositive for low-active Ab-proteases from which 22% of the seropositive relatives
established were being monitored for 2 years whilst demonstrating a stable growth of the Ab-associated proteolytic activity.
Moreover, some of the low-active Ab-proteases in persons at MS-related risks (at subclinical stages of MS), and primary
clinical and MRT manifestations observed were coincided with the activity to have its mid-level reached. Registration in
the evolution of highly immunogenic Ab-proteases would illustrate either risks of transformation of subclinical stages into
clinical ones, or risks of exacerbations to develop. The activity of Ab-proteases in combination with the sequence-specificity
would confirm a high subclinical and predictive (translational) value of the tools as applicable for personalized monitoring
protocols. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism or could be
designed for the development of principally new catalysts with no natural counterparts. Further studies on targeted Ab-
mediated proteolysis may provide a translational tool for predicting demyelination and thus the disability of theMS patients.
Biography
Sergey Suchkov graduated fromAstrakhan StateMedical University and was awarded withMD andmaintained his PhD and Doctor’s degree. He was working
for Helmholtz Eye Research Institute and Moscow Regional Clinical Research Institute. He was a Secretary-in-Chief of the Editorial Board, Biomedical
Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. Currently, he is a Director of
Center for Personalized Medicine, Sechenov University; Chair of the Department for Translational Medicine, Moscow Engineering Physics University and
Secretary General of United Cultural Convention, Cambridge, UK. He is a Member of the New York Academy of Sciences; American Chemical Society;
American Heart Association; AMEE, Dundee, UK; EPMA, Brussels, EU; PMC, Washington, DC, USA and ISPM, Tokyo, Japan.
Sergey Suchkov
I M Sechenov First Moscow State Medical University, Russia